Type: device
Status: FDA Approved — Commercially Available
Developer: Senseonics
The Eversense 365 is the first fully implantable CGM lasting a full year. FDA approved February 2025. Fluorescence-based sensor implanted in the upper arm during a brief in-office procedure. Real-world data shows MARD of 8.5%, comparable to transcutaneous sensors, with 99.5% data availability and no adhesive-related skin issues.
A polymeric sensor coated with glucose oxidase and fluorescent indicator molecules is implanted subcutaneously. Glucose binds to the indicator, modulating fluorescence measured by an external transmitter worn over the sensor. Data streams to a smartphone app.
Year: 2025